Oruka Therapeutics, Inc.
ORKANext catalyst
ORKA-001
Plaque Psoriasis
Get an email about ORKA's next catalysts
Track Oruka Therapeutics (ORKA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
ORKA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.68 | FQ end Sep/2026 | Call: tbd
ORKA-001 Phase 2 Est. Readout (EVERLAST-B)
Primary completion for ORKA-001 trial (NCT07290569) in Plaque Psoriasis
SourceORKA-002 Phase 2 Est. Readout
Primary completion for ORKA-002 trial (NCT07474792) in Plaque Psoriasis
SourceMarket Overview
Stock performance and key metrics
ORKA-001 Induction Dose
Plaque Psoriasis
ORKA-001
Plaque Psoriasis
ORKA-002
Plaque Psoriasis
ORKA-001 Maintenance Dose
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ORKA-001 Induction Dose | Phase 2 | Plaque Psoriasis | - | - |
ORKA-001 | Phase 2 | Plaque Psoriasis | - | - |
ORKA-002 | Phase 2 | Plaque Psoriasis | - | - |
ORKA-001 Maintenance Dose | Phase 2 | Plaque Psoriasis | - | - |
Frequently asked questions
What is in Oruka Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Oruka Therapeutics, Inc.'s (ORKA) pipeline across Phase 2. Its lead program is ORKA-001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oruka Therapeutics, Inc.'s next FDA catalyst?→
Oruka Therapeutics, Inc.'s (ORKA) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ORKA biotech catalysts?→
Add ORKA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oruka Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.